

Intramyocellular lipid content in human skeletal muscle

Citation for published version (APA):

Schrauwen-Hinderling, V. B., Hesselink, M. K., Schrauwen, P., & Kooi, M. E. (2006). Intramyocellular lipid content in human skeletal muscle. *Obesity Research*, 14(3), 357-367. <https://doi.org/10.1038/oby.2006.47>

Document status and date:

Published: 01/01/2006

DOI:

[10.1038/oby.2006.47](https://doi.org/10.1038/oby.2006.47)

Document Version:

Publisher's PDF, also known as Version of record

Document license:

Taverne

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

Intramyocellular Lipid Content in Human Skeletal Muscle

Vera B. Schrauwen-Hinderling,*† Matthijs K.C. Hesselink,† Patrick Schrauwen,† and Marianne Eline Kooi*

Abstract

SCHRAUWEN-HINDERLING, VERA B., MATTHIJS K.C. HESSELINK, PATRICK SCHRAUWEN, AND MARIANNE ELINE KOOI. Intramyocellular lipid content in human skeletal muscle. *Obesity*. 2006;14:357–367.

Fat can be stored not only in adipose tissue but also in other tissues such as skeletal muscle. Fat droplets accumulated in skeletal muscle [intramyocellular lipids (IMCLs)] can be quantified by different methods, all with advantages and drawbacks. Here, we briefly review IMCL quantification methods that use biopsy specimens (biochemical quantification, electron microscopy, and histochemistry) and non-invasive alternatives (magnetic resonance spectroscopy, magnetic resonance imaging, and computed tomography).

Regarding the physiological role, it has been suggested that IMCL serves as an intracellular source of energy during exercise. Indeed, IMCL content decreases during prolonged submaximal exercise, and analogously to glycogen, IMCL content is increased in the trained state. In addition, IMCL content is highest in oxidative, type 1 muscle fibers. Together, this, indeed, suggests that the IMCL content is increased in the trained state to optimally match fat oxidative capacity and that it serves as readily available fuel. However, elevation of plasma fatty acid levels or dietary fat content also increases IMCL content, suggesting that skeletal muscle also stores fat simply if the availability of fatty acids is high. Under these conditions, the uptake into skeletal muscle may have negative consequences on insulin sensitivity.

Besides the evaluation of the various methods to quantify IMCLs, this perspective describes IMCLs as valuable energy stores during prolonged exercise, which, however, in the absence of regular physical activity and with overconsumption of fat, can have detrimental effects on muscular insulin sensitivity.

Introduction

In 1913, Greene reported that the dark muscle of the King salmon is characterized by “the enormous loading of fat at all stages of the life cycle, but especially at the time the spawning migration begins” and that “the stored fat is gradually eroded during the migration” (1). These observations were followed by quantitative investigations of human muscle when the first intramyocellular lipid (IMCL)¹ data from biochemical analysis of biopsies from the human quadriceps were published in 1969 by Morgan et al. (2). Later, quantitative morphological determination of IMCLs was performed by electron microscopy (EM) in the beginning of the 1970s (3,4).

Using EM, individual lipid droplets in myocytes could be visualized in the sarcoplasm, usually in direct contact with mitochondria (5). This direct contact with mitochondria led to the hypothesis that the lipid droplets serve as a fuel for mitochondrial fat oxidation, in situations where rapid supply of fat is needed, such as during exercise. It is long recognized that during endurance exercise, fat oxidation contributes significantly to the energy requirements of skeletal muscle. While fatty acids (FAs) stored in adipose tissue as triglycerides first have to undergo lipolysis, be released in the blood, and be transported to the active muscle for oxidation, IMCL stores would be a readily available substrate source during endurance exercise. Indeed, tracer studies have reported that oxidation of the IMCL stores contribute to the energy used during exercise (6–8), although

Received for review March 18, 2005.

Accepted in final form December 23, 2005.

The costs of publication of this article were defrayed, in part, by the payment of page charges. This article must, therefore, be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

*Department of Radiology, University Hospital Maastricht, Maastricht, The Netherlands; and †Nutrition and Toxicology Research Institute Maastricht, NUTRIM, Maastricht University, Maastricht, The Netherlands.

Address correspondence to Vera B. Schrauwen-Hinderling, Department of Radiology, University Hospital Maastricht, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands.

E-mail: vhi@rdia.azm.nl

Copyright © 2006 NAASO

¹ Nonstandard abbreviations: IMCL, intramyocellular lipid; EM, electron microscopy; FA, fatty acid; FFA, free FA; DAG, diacylglycerol; MRS, magnetic resonance spectroscopy; ¹H-MRS, proton MRS; EMCL, extramyocellular lipid; CT, computed tomography; MRI, magnetic resonance imaging; E% fat, percentage of energy as fat.

results are equivocal (9). Therefore, the question to what extent IMCL is used as a substrate source during exercise is still an ongoing debate.

Initially, the interest in the physiological role of IMCL came mainly from the field of exercise physiology. However, this changed dramatically after the finding that IMCL accumulation was associated with insulin resistance (10–12), an important risk factor for type 2 diabetes.

Recently, several reviews have been published that address the role of IMCLs during exercise (13,14) and in skeletal muscle insulin resistance (15–21). Here, we aim to provide an overview of the most important determinants of IMCL content along with possible physiological functions of IMCL stores. To this end, we will include discussion of the methodology presently available to examine IMCL content with consideration of the drawbacks and advantages of the distinct methods and their applicability in answering questions toward the physiological role of IMCLs. We hypothesize that the capability of skeletal muscle to store FAs as IMCLs has physiological relevance in providing rapidly available energy during physical activity. With the present lifestyle of low physical activity and overconsumption of fatty foods in westernized society, this capability may have a downside. Continuous supply of fat to the muscle without concomitant oxidation will have negative effects on insulin sensitivity.

Quantification of IMCL Content

Biochemical Analysis of Biopsies

There are several ways to quantify IMCL content, all with their pros and cons. Biochemical analysis of biopsy data has been used extensively to quantify IMCL content. When using this method, muscle biopsy samples are freed from any visible fat, specimens are freeze-dried, and a chloroform-methanol extraction is used to isolate lipids. The triacylglycerols are hydrolyzed, and the final concentration is calculated from the amount of released glycerol or free FAs (FFAs) in solution. Although all visible adipose tissue is removed from the samples, small quantities of residual adipose tissue can have a large effect on the outcome, usually resulting in a high variability of the data; an inter-biopsy variation of 23% has been reported (22), which renders this method insensitive to the detection of small changes. In well-trained subjects, who tend to have very little adipose tissue, the biochemical quantification is more reliable, and a coefficient of variation of 12.3% has been reported (23). The method can be refined by microdissection of the muscle specimens (24) or by mechanically isolating the individual muscle fibers from freeze-dried samples using a binocular.

EM

Another approach, in which contamination of adipose tissue is not a problem, is the morphometric analysis of




Figure 1: Quantification of IMCLs by EM. The figure shows an ultrathin section of rat tibialis anterior muscle. The white vacuoles are lipid droplets (IMCLs).

muscle biopsy slices with EM. With a magnification of 20,000 \times to 30,000 \times , the volume density of lipid droplets inside myocytes can be analyzed in ultrathin slices (50 to 100 nm) of biopsy samples (3,4,25) (Figure 1). A disadvantage of this method is that it is limited to a very small muscle volume, and many measurements need to be done to obtain a reliable quantitative measure of whole-muscle IMCL content, making the analysis of data very elaborate. However, an advantage of EM is that it yields a lot of other morphological information such as the localization relative to mitochondria, the contact area between lipid droplets and mitochondria, and the intracellular localization of the droplets (subsarcolemmal vs. intramyofibrillar). Furthermore, differences in cytoarchitecture (z-line thickness) (26) can be used to identify the fiber type under examination.

Histochemistry

Alternatively, cross-sectional, thin slices ($\pm 5 \mu\text{m}$) of biopsy specimens can be treated with Oil Red O, which visualizes the lipid droplets with an orange-red tint under the light microscope. Oil Red O has long been used in light microscopy as a neutral lipid dye (27), but only recently has this dye been employed for truly quantitative analysis of IMCLs (28). Digital capturing of images and subsequent quantitative image analysis yield a percentage of the total cell area occupied by lipids. Interestingly, the Oil Red O dye is fluorescent; therefore, IMCLs can also be analyzed under a fluorescence microscope and quantified with the according software (29) (Figure 2). This also allows simultaneous performance of immunohistochemical stainings on the same




Figure 2: Quantification of IMCLs by histochemistry. The figure shows a stained section of rat tibialis anterior muscle. The red fluorescent signal originates from Oil Red O, showing IMCLs; the blue fluorescent signal originates from a laminin staining, showing the cell membranes.

slices (29), e.g., to determine fiber type or proteins involved in FA handling. A disadvantage of this methodology, however, is that Oil Red O stains all neutral lipids and, therefore, most likely also stains FA metabolites, such as diacylglycerol (DAG).

Magnetic Resonance Spectroscopy (MRS)

With the demonstration that IMCLs can be quantified by proton MRS (^1H -MRS) with a standard clinical whole-body scanner (30,31), it became possible to determine the IMCL content non-invasively, and repeated measurements in the same muscle volume could be done. In contrast to EM or the Oil Red O method, where lipids can be visualized within single muscle fibers, ^1H -MRS measures lipid content over a larger muscle area. Because the resonance frequency of small lipid droplets surrounded by an aqueous phase (sarcoplasm) is different from that of lipids surrounded by bulk lipid (as in adipose tissue) and because additionally the resonance frequency of extramyocellular lipids (EMCLs; lipid layers between muscle bundles) depends on the orientation of the layer relative to the main magnetic field, ^1H -MRS can differentiate between IMCLs and adipose tissue between muscle bundles (31,32) (Figure 3). The coefficients of variation of repeated quantification of IMCLs by MRS measurements typically are ~6% to 14% (31,33–37). Importantly, ^1H -MRS can be used to investigate all muscles of the upper or lower leg and/or arm, and the volume of investigated muscle tissue is relatively big (2 to 3 cm^3 for




Figure 3: Quantification of IMCLs by MRS. The figure shows an ^1H -MRS spectrum from a human vastus lateralis muscle. The arrows point out the peaks originating from the methylene protons of EMCLs and IMCLs, respectively.

single voxel spectroscopy). Either a single volume of interest (voxel) or a matrix of many voxels (if magnetic resonance spectroscopic imaging is used) can be investigated. Therefore, by using magnetic resonance spectroscopic imaging, all of the muscles of, e.g., the lower leg can be investigated in one measurement (38).

The main drawback of ^1H -MRS is that although two separated peaks are detectable, the IMCL and EMCL peaks do partially overlap, and sophisticated peak-fitting software is needed to quantify the two peaks separately. Especially in obese subjects, the high number of EMCLs makes it difficult to position the voxel in an area with few EMCLs, and a large EMCL peak will overlap more severely with the IMCL peak. The true separation of IMCLs and EMCLs and the non-invasiveness of the method make MRS very often the method of choice. Because the measurement can ensure the repeated investigation of identical muscle volumes in a patient-friendly, non-invasive way, the method is especially interesting to monitor the effect of interventions.

Computed Tomography (CT) and Magnetic Resonance Imaging (MRI)

Other non-invasive techniques, namely CT and MRI (39,40), are also used to quantify fat content in skeletal muscle. With these imaging techniques, the fat content of muscle is determined based on different signal intensities between fat and lean muscle tissue. A drawback of these imaging techniques is, however, that they cannot distinguish between a pixel containing muscle tissue with a high IMCL content and a pixel with muscle tissue with low IMCL content but partially filled with adipose tissue (EMCLs) because both pixels can have the same signal intensity (this phenomenon is called partial volume effect). The reproducibility of CT measurements is very high, and coefficients of variation of 0.51% to 0.85% have been reported (41).

Table 1. Comparison of different methods to quantify IMCL content

Method	Advantage	Disadvantage
Electron microscopy	<ol style="list-style-type: none"> 1. Depicting additional structures (e.g. mitochondria) 2. Not biased by EMCL 	<ol style="list-style-type: none"> 1. Invasive (biopsy specimen) 2. Very small area investigated 3. Laborious
Histochemistry (Oil red O)	<ol style="list-style-type: none"> 1. Possibility of other (immunofluorescent) stainings 2. Not biased by EMCL 	<ol style="list-style-type: none"> 1. Invasive (biopsy specimen)
MRS	<ol style="list-style-type: none"> 1. Non-invasive, patient friendly 2. Repeated measurements in identical volume 3. Relatively large volume investigated 	<ol style="list-style-type: none"> 1. Partial overlap of IMCL and EMCL peak 2. Absolute quantification is laborious, usually relative measures presented
Biochemical analysis	<ol style="list-style-type: none"> 1. Extensively used in literature (lots of reference data) 	<ol style="list-style-type: none"> 1. Invasive (biopsy specimen) 2. Large variation, contamination by adipose tissue likely
CT	<ol style="list-style-type: none"> 1. Non-invasive, patient friendly 2. Repeated measurements in identical volume 3. Large volume investigated 	<ol style="list-style-type: none"> 1. No true separation of IMCL and EMCL 2. Exposure to ionizing radiation
MRI	<ol style="list-style-type: none"> 1. Non-invasive, patient friendly 2. Repeated measurements in identical volume 3. Large volume investigated 	<ol style="list-style-type: none"> 1. No true separation of IMCL and EMCL

EMCL, extramyocellular lipid; IMCL, intramyocellular lipid; MRS, magnetic resonance spectroscopy; CT, computed tomography; MRI, magnetic resonance imaging.

When comparing the different methods, it has been shown that ^1H -MRS data correlate closely with EM data (25), and a good correlation between ^1H -MRS data and Oil Red O staining was reported as well (42). However, the correlation of chemical analysis with ^1H -MRS and EM was poor (25), probably due to the high variability of the chemical analysis, as discussed above.

Therefore, ^1H -MRS, EM, and Oil Red O stainings are all valuable methods to quantify IMCL content, whereas biochemical methods should only be used if refinements to diminish contamination of adipose tissue are applied. ^1H -MRS has the advantage of being non-invasive. Other non-invasive methods, namely CT and MRI, cannot truly separate IMCLs and EMCLs. For an overview of the different methods, see Table 1.

IMCL as an Intracellular Source of Fuel

Early isotope studies (8) indicated that during exercise not all of the oxidized fat could be accounted for by oxidation of plasma FFA, leading to the suggestion that the lipid droplets inside the muscle cells serve as important fuel during exercise. Especially during prolonged exercise, IMCL is thought to be an important fuel source, and the oxidation of IMCLs might have a sparing effect on glyco-gen oxidation. Data from biochemical analysis are equivocal on the effect of acute exercise, with some laboratories

reporting a decrease in IMCL content (43–49), whereas others did not (50–54). This discrepancy may be due to the high variability of the biochemical IMCL determination, especially in untrained subjects, where more adipose tissue can contaminate the IMCL determination (14). In contrast to biochemical analysis, EM data showed that IMCLs decreased by 42% in the gastrocnemius muscle after completion of a marathon race (55), and IMCLs were nearly depleted after a 100-km run in seven well-trained subjects (56). These results are in line with more recent ^1H -MRS results, showing a consistent decrease in IMCL content after acute exercise (31,33,57–64). Only a high-intensity interval protocol reported no decrease of IMCL content after exercise when ^1H -MRS was employed (34). The latter is not surprising because during high-intensity interval protocols, carbohydrate is the main fuel oxidized. In summary, there is little doubt that IMCLs are, indeed, oxidized during endurance exercise and can serve as a readily available energy source during exercise.

Fat Content of Different Muscles

Most studies examining IMCL content have been limited to a few muscle groups. With ^1H -MRS especially, the muscles of the calf have been extensively studied. In the calf, the highest fat contents have been found in the medial part of the soleus muscle and lower values (by a factor of 2

to 3) in the tibialis anterior and posterior (65) and the gastrocnemius muscle (38). This matches the different fiber-type distribution of these muscles and their substrate use. The soleus muscle is a more oxidative muscle relying more on fat oxidation than the tibialis and gastrocnemius muscles. Likewise, the soleus muscle has a high percentage (~88%) (66), whereas the gastrocnemius muscle has a lower percentage (~50%) of type 1 fibers (66). The fiber composition of the tibialis anterior muscle lies in between (~70% of type 1 fibers). EM (67) and histochemistry (Oil Red O) (42,68), indeed, showed that oxidative type 1 fibers are characterized by a higher fat content than glycolytic type 2 fibers. In addition, oxidative type 1 fibers contain more mitochondria, suggesting that the IMCL droplets can serve as a rapid available source of energy for mitochondrial oxidation.

In summary, consistent with the observation that IMCLs can serve as an energy source during exercise, IMCL content is dependant on the fiber-type composition of muscles, with oxidative muscle groups being characterized by a high IMCL content.

Replenishment after Exercise

For IMCLs to be used during repeated exercise bouts, they need to be replenished in the post-exercise state. Analogous to a high-carbohydrate diet speeding up the replenishment of glycogen stores, investigators examined whether the replenishment of IMCL stores is faster on a high-fat diet.

IMCL content assessed with biochemical methods during the 24 hours after an exercise bout on either a high-fat [68% of the energy as fat (E% fat)] or a low-fat (5 E% fat) diet showed an increase on the high-fat diet, whereas it remained unchanged on the low-fat diet (54). The investigation with ¹H-MRS of the time course of IMCL recovery after an exercise-induced decrease in IMCLs revealed that the IMCL content returned to a level higher than baseline (supercompensation of 30% to 45%) after 30 hours on a high-fat diet (55 E% fat), whereas on a low-fat diet (15 E% fat), the IMCL content did not recover within 30 hours (69). Also, in female runners, IMCL content was restored to baseline 22 hours after running exercise on a moderate-fat diet (35 E% fat), with a supercompensation of IMCL content on the moderate-fat diet after 70 hours. In contrast, on a low-fat diet (10 E% fat), IMCL content did not recover in the 70 hours post-exercise (62). Similarly, we reported that in healthy male athletes, the replenishment of IMCL content on a moderate-fat diet (39 E% fat) 48 hours after exercise was complete, whereas IMCL content on a typical athletes' diet (24 E% fat) did not recover in 48 hours (42). Interestingly, the difference in IMCL replenishment between the low- and moderate-fat diets was only visible in type 1 (oxidative) muscle fibers (42).

Given that IMCL is used during prolonged exercise, replenishment of IMCL content post-exercise could poten-

tially improve performance. However, when a 120-minute time trial was used to deplete IMCL stores and was followed by 24 hours with either a high-fat or a high-carbohydrate diet, the performance on a subsequent self-paced cycling time trial was lower with the high-fat diet (54). Also, in studies focusing on performance after long-term adaptation to a high-fat diet, results are equivocal with studies reporting a positive effect (70), a negative effect (71), or no change in performance (72,73), and one study showing no effect on high-intensity exercise but a positive effect on submaximal exercise (74).

Therefore, although IMCL is used during exercise, no strong evidence is available yet that IMCL content is limiting athletic performance (for recent review, see Ref. 75).

In summary, analogous to glycogen levels being rapidly replenished when glucose is ingested after exercise, high-fat diets accelerate the replenishment of IMCL stores after exercise. Although for glycogen it is generally accepted that such repletion is essential for subsequent performance, such evidence is not available in regard to the high-fat-induced replenishment of IMCLs. This does not imply that high IMCL content is not essential to athletic performance but might be explained by the lack of studies examining the impact of IMCL content, while keeping glycogen levels constant, on endurance performances that lead to a substantial depletion of IMCLs (as, for example, a 100-km run) (56).

Endurance Training

As discussed above, during exercise, both intramyocellular glycogen and lipid stores are used as energy source, dependent on the exercise intensity, and both substrate stores are replenished in the recovery phase post-exercise. With endurance training, glycogen levels are elevated, which promotes fatigue resistance. Analogously to glycogen, it might be expected that IMCL content is increased in the endurance-trained state, too. With biochemical analysis of IMCLs, some authors reported increased IMCL content after 4 to 6 weeks of training (2,76), whereas others reported no change after 12 weeks of training at high intensity (51) or even a decrease in IMCL content (77). These equivocal results are probably again due to the high variability of the biochemical method.

EM revealed 2.5 times higher IMCL content in the vastus lateralis of well-trained orienteers (3) and 2.5 times higher IMCL content in the gastrocnemius muscle of elite rowers compared with controls (78). With 6 to 8 weeks of endurance training, IMCL content increased up to 3.4 times in the vastus lateralis muscle (79,80). Although almost all studies using EM and involving endurance training reported increased IMCL content after training, the change did not always reach statistical significance (81,82), and one study reported no difference in IMCL content of the gastrocnemius of endurance-trained athletes and untrained subjects

(83). An increased IMCL content in trained subjects limited to type 1 fibers has been reported in some studies (84,85), whereas a fiber-type-specific increase in IMCL content in types 2a and 2b fibers was reported by others (67), and a higher IMCL content in trained cross-country runners was limited to type 2a fibers (86). Similarly to the results from EM, Oil Red O stainings report large differences (50% to 70%) between trained and untrained subjects (11,68) and increased IMCL content (+12%) after a 12-week training period in older subjects (87). The EM and the histological data are in line with ¹H-MRS data, which report higher IMCL content in trained subjects, compared with untrained (61,88). We recently showed with ¹H-MRS that a 2-week training program in young sedentary male subjects resulted in a 42% increase in IMCL content (33), thereby confirming results obtained with EM and Oil Red O (87).

Taken together, independent of the methodology used, there is unequivocal evidence that IMCL content is increased on endurance training, again consistent with IMCL being an energy source for physical activity. Because endurance training also increases the relative amount of type 1, oxidative muscle fibers, this may partly explain the increase in IMCLs (11,68).

High-Fat Diets

The results discussed so far suggest that IMCL functions as a rapidly available energy source to deliver fuel for the mitochondrial ATP formation necessary for muscle contraction. As with glycogen, the levels of these intramuscular substrate stores are influenced by the diet, at least in the recovery phase after exercise. Many investigators have also examined the effect of high-fat diets per se, and not limited to athletes, on IMCL content. With biochemical methods, triglyceride content in skeletal muscle has been reported to increase by 36% to 90% after high-fat feeding periods ranging from 24 hours to 7 weeks (54,89–93). Similarly, data from EM showed a 130% increase in IMCL content after 5 weeks of a high-fat diet (94). Using ¹H-MRS, the effect of high-fat diets (55 to 60 E% fat) has been investigated after 2 to 3 days (95,96), and after 1 week (97); in all three studies, an increase (between 48% and 56%) in IMCL content was reported.

The reason for this increase in IMCLs on a high-fat diet is not yet clear. We and others have shown that a high-fat diet increases fat oxidation, which is not due to an increased oxidation of FFA (91,98). This suggests that an increased IMCL (and/or very low-density lipoprotein) oxidation occurs after a high-fat diet, suggesting that the increase in IMCLs drives increased IMCL oxidation. Alternatively, high-fat feeding promotes overfeeding and a positive fat balance. The surplus of fat is mainly stored in adipose tissue but also in non-adipose tissue such as skeletal muscle. In this respect, the increase in IMCLs on a high-fat diet could also simply be seen as an excessive storage of a surplus of

circulating FAs. In that respect, it is interesting to note that obese subjects are characterized not only by increased adipose tissue but generally also by increased plasma lipid concentrations and by high IMCL content and low fat oxidative capacity (28). Additionally, in obese subjects with normal fat oxidation, IMCL content was normal too (99). This further suggests that the increase in IMCLs may be simply due to a mismatch between delivery to and oxidative capacity of skeletal muscle.

In summary, a high-fat diet increases IMCL stores, which may simply be due to a positive fat balance when changing to a high-fat diet. In physically inactive humans consuming a high-energy, high-fat diet, a positive energy and fat balance may occur chronically, resulting in fat accumulation in adipose tissue and probably also in skeletal muscle.

High FFA Plasma Concentrations

In accordance with the suggestion above, other conditions with high FA availability have also led to increases in IMCL content. The acute elevation of plasma FFA by infusions has resulted in increased IMCL content (95,100). Also, during fasting, lipolysis is stimulated, and plasma FFA concentrations are elevated. Interestingly, it has been reported that 72 hours of fasting increased IMCL content (101).

In line with an elevation of IMCL in the presence of high FFA plasma concentrations, we found that exercise that was accompanied by increased plasma FFA resulted in a decrease in IMCLs in the exercising legs but an increase of IMCL content in the inactive, non-exercising muscle (63). The increase in IMCLs under conditions of high FA availability can simply be due to a higher supply of fat to the muscle. Alternatively, non-active muscle could act as a buffer for elevated plasma FFA by taking them up from the circulation. High plasma concentrations of FA can harm the endothelial wall; therefore, their removal from the circulation is important. Although adipose tissue is readily taking up and storing FA, muscle tissue also seems to fulfill this function if FA availability is high. In this way, both the white adipose tissue and the muscle help to prevent or limit elevation of circulating plasma FA levels, and the stored IMCLs could serve as an energy source when lipid supply is decreasing. However, as we are all aware, in our westernized society with a surplus of dietary energy available, periods of low lipid supply are scarce, resulting in continued high levels of IMCLs in non-active muscle tissues.

In summary, an elevation of plasma FFAs results in increased IMCL content. It is yet unclear whether this is a passive mechanism or whether skeletal muscle actively buffers FFA plasma concentrations.

Association with Insulin Resistance

The prevalence of insulin resistance and type 2 diabetes is increasing rapidly, and high-energy intake and lack of phys-

ical activity in westernized societies are considered major risk factors. The development of insulin resistance coincides with the accumulation of IMCLs. With biochemical methods, a correlation of triglyceride content with insulin resistance in Pima Indians was reported (12), and a similar correlation was shown in sedentary subjects with histochemical methods (11) and with $^1\text{H-MRS}$ (10). Interestingly, IMCL content has been described as an early marker of the development of insulin resistance. Philipps et al. (102) investigated normoglycemic women and found a negative relation between increased triglyceride content (assessed by histological and biochemical methods) and decreased glycogen synthase activity. Furthermore, histochemically determined high IMCL contents were related to high waist-to-hip ratios and high FFA plasma concentrations. These data suggest that high IMCL content, perhaps due to high plasma FA levels, can lead to the development of insulin resistance, although the possibility cannot be excluded that insulin resistance leads to the accumulation of IMCLs. To investigate early aberrations in metabolism in the pathogenesis of type 2 diabetes, a valuable approach is the investigation of healthy subjects with a high risk of developing diabetes in later life, such as family members of patients with type 2 diabetes. With $^1\text{H-MRS}$, Perseghin et al. (103) showed that first-degree relatives of type 2 diabetic patients had higher IMCL content (and were less insulin sensitive) than matched controls. Similarly, the offspring of type 2 diabetic patients were investigated (104) and divided into insulin-sensitive and -resistant subjects. The results showed that the insulin-resistant subjects had a higher IMCL content than the insulin-sensitive counterparts. The increased IMCL content in insulin-resistant but otherwise healthy subjects suggests that the accumulation of IMCLs is an early step in the development of type 2 diabetes. Also, in overt diabetes, IMCL content is severely increased. Early data from biochemical analysis of biopsy samples revealed a 6-fold excess of triglyceride content in subjects with type 2 diabetes (105). This was confirmed by histochemical methods revealing higher IMCL content in type 2 diabetic subjects, compared with obese or lean controls (11). In accordance, obese subjects who had normal insulin sensitivity were also characterized by normal IMCL content (99).

The data above show clearly that an increased IMCL content is associated with insulin resistance if training status is not confounding. Weight loss is well known to improve insulin sensitivity in overweight, insulin-resistant subjects, and this is accompanied by a decreased IMCL content. Histochemically determined IMCL content decreased by 30% after bariatric surgery and extreme weight loss (106,107).

To summarize, IMCL content is a marker of insulin resistance in diabetic and healthy physically non-active subjects, and the accumulation of IMCLs has been shown to be an early phenomenon in the development of diabetes.

Mechanisms of Decreased Insulin Sensitivity

High IMCL content, thus, seems to be associated with the development of insulin resistance, which is in contrast to the observations that endurance training leads to an increase in IMCL content, too. This has been described as the training paradox in the literature (11). However, as reviewed above, IMCLs can be increased for two different reasons: a functional increase, whereby IMCL serves as a rapidly available energy source; and a pathophysiological increase, whereby increased IMCL is merely due to a continuous oversupply of fat. In the former condition, the increase in IMCLs can only be functional if at the same time the capacity to liberate these IMCLs and rapidly divert them to oxidation is also increased. Indeed, gene expression of a key component of FA transport (carnitine palmitoyltransferase) and the fat oxidative capacity are also increased in the trained state (108). In the second condition, however, the increased IMCL content most likely is not accompanied by such a strongly increased fat oxidative capacity. Indeed, Goodpaster et al. (11) suggested that fat oxidative capacity might be more important than IMCL content in determining insulin sensitivity, and Petersen et al. (109) reported decreased mitochondrial function (oxidative capacity) in the insulin-resistant offspring of type 2 diabetes patients, compared with insulin-sensitive controls. In the search for a functional explanation for the relation between IMCL and insulin sensitivity, it has been suggested that lipid metabolites such as fatty acyl-CoA or DAG are more likely to intervene with insulin signaling than IMCLs per se. DAG is the intermediate between fatty acyl-CoA that can enter the mitochondria for oxidation and triacylglycerol, the form in which lipids are stored in muscle. As outlined above, a functional increase in IMCLs is accompanied by an increased capacity to divert IMCLs to oxidation; therefore, the level of the lipid intermediates will stay low. However, in the condition of continuous fat oversupply, the increased IMCL is not accompanied by a sufficiently increased fat oxidative capacity; therefore, not only IMCLs but also DAG and fatty acyl-CoA will increase. As mentioned, the latter two have been shown to be able to interfere with insulin signaling (for review, see ref. 110).

In summary, although the accumulation of IMCLs coincides with the development of insulin resistance, the relationship is most likely indirect. Various intermediates of fat metabolism have been named as candidates to be the culprits of decreasing insulin action. As the intermediates accumulate in situations with high fat availability and low fat oxidation, the balance between availability and oxidation may be crucial.

Concluding Remarks and Future Perspective

The physiological function of fat stores in the muscle is to serve as a readily available energy source during exercise.

Although physical activity levels in our westernized society are generally very low, this capacity to store fat inside muscle may have conferred an evolutionary advantage to permit physical activity during cycles of feast and famine. In that respect, it was recently suggested that humans' endurance-running capacity may have been instrumental in the evolution of *Homo sapiens* (111). Alternatively, it has been suggested that temporal insulin resistance that accompanies the fasting-induced accumulation of IMCLs may have been instrumental in evolution to spare glucose for the brain during periods of famine (15). Nowadays, however, in westernized society, the importance of having high IMCL levels may have faded due to the low levels of physical activity and the continuous availability of food. However, the capability to store IMCLs is still preserved; as a consequence, in conditions of high circulating FA levels or high dietary lipid supply, muscle may act as a sink for circulating FAs. In these conditions in which IMCLs are not being used for oxidation, IMCLs and their intermediates have a negative impact on insulin signaling and induce insulin resistance. Therefore, the preserved capacity to store fat in muscle may nowadays have detrimental effects on insulin sensitivity, especially when IMCLs are not being used as substrate. In that respect, the capacity to use IMCLs may be more important than the magnitude of IMCL levels per se in determining the negative effects on insulin sensitivity.

Acknowledgment

This study was supported by VIDI Research Grant 917.66.359 for innovative research from the Netherlands Organization for Scientific Research (to M.H.) and a fellowship of the Royal Netherlands Academy of Arts and Sciences (to P.S.).

References

1. **Greene CW.** The storage of fat in the muscular tissue of the King salmon and its resorption during the fast of the spawning migration. *Bull Bur Fisheries*. 1913;33:73–138.
2. **Morgan TE, Short FA, Cobb LA.** Effect of long-term exercise on skeletal muscle lipid composition. *Am J Physiol*. 1969;216:82–6.
3. **Hoppeler H, Luthi P, Claassen H, Weibel ER, Howald H.** The ultrastructure of the normal human skeletal muscle: a morphometric analysis on untrained men, women and well-trained orienteers. *Pflugers Arch*. 1973;344:217–32.
4. **Jerusalem F, Engel AG, Peterson HA.** Human muscle fiber fine structure: morphometric data on controls. *Neurology*. 1975;25:127–34.
5. **Hoppeler H.** Exercise-induced ultrastructural changes in skeletal muscle. *Int J Sports Med*. 1986;7:187–204.
6. **Havel RJ, Carlson LA, Ekelund LG, Holmgren A.** Turn-over rate and oxidation of different free fatty acids in man during exercise. *J Appl Physiol*. 1964;19:613–8.
7. **Havel RJ, Pernow B, Jones NL.** Uptake and release of free fatty acids and other metabolites in the legs of exercising men. *J Appl Physiol*. 1967;23:90–9.
8. **Issekutz B Jr, Issekutz AC, Nash D.** Mobilization of energy sources in exercising dogs. *J Appl Physiol*. 1970;29:691–7.
9. **Steffensen CH, Roepstorff C, Madsen M, Kiens B.** Myocellular triacylglycerol breakdown in females but not in males during exercise. *Am J Physiol Endocrinol Metab*. 2002;282:E634–42.
10. **Krssak M, Falk Petersen K, Dresner A, et al.** Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a ¹H NMR spectroscopy study. *Diabetologia*. 1999;42:113–6.
11. **Goodpaster BH, He J, Watkins S, Kelley DE.** Skeletal muscle lipid content and insulin resistance: evidence for a paradox in endurance-trained athletes. *J Clin Endocrinol Metab*. 2001;86:5755–61.
12. **Pan DA, Lillioja S, Kriketos AD, et al.** Skeletal muscle triglyceride levels are inversely related to insulin action. *Diabetes*. 1997;46:983–8.
13. **van Loon LJ.** Use of intramuscular triacylglycerol as a substrate source during exercise in humans. *J Appl Physiol*. 2004;97:1170–87.
14. **Watt MJ, Heigenhauser GJ, Spriet LL.** Intramuscular triacylglycerol utilization in human skeletal muscle during exercise: is there a controversy? *J Appl Physiol*. 2002;93:1185–95.
15. **Stannard SR, Johnson NA.** Insulin resistance and elevated triglyceride in muscle: more important for survival than “thrifty” genes? *J Physiol*. 2004;554:595–607.
16. **Goodpaster BH, Wolf D.** Skeletal muscle lipid accumulation in obesity, insulin resistance, and type 2 diabetes. *Pediatr Diabetes*. 2004;5:219–26.
17. **Russell AP.** Lipotoxicity: the obese and endurance-trained paradox. *Int J Obes Relat Metab Disord*. 2004;28(Suppl 4):S66–71.
18. **Machann J, Haring H, Schick F, Stumvoll M.** Intramyocellular lipids and insulin resistance. *Diabetes Obes Metab*. 2004;6:239–48.
19. **Schrauwen P, Hesselink MK.** Oxidative capacity, lipotoxicity, and mitochondrial damage in type 2 diabetes. *Diabetes*. 2004;53:1412–7.
20. **Krssak M, Roden M.** The role of lipid accumulation in liver and muscle for insulin resistance and type 2 diabetes mellitus in humans. *Rev Endocr Metab Disord*. 2004;5:127–34.
21. **Kelley DE.** Influence of weight loss and physical activity interventions upon muscle lipid content in relation to insulin resistance. *Curr Diab Rep*. 2004;4:165–8.
22. **Wendling PS, Peters SJ, Heigenhauser GJ, Spriet LL.** Variability of triacylglycerol content in human skeletal muscle biopsy samples. *J Appl Physiol*. 1996;81:1150–5.
23. **Watt MJ, Heigenhauser GJ, O'Neill M, Spriet LL.** Hormone-sensitive lipase activity and fatty acyl-CoA content in human skeletal muscle during prolonged exercise. *J Appl Physiol*. 2003;95:314–21.
24. **Guo Z, Mishra P, Macura S.** Sampling the intramyocellular triglycerides from skeletal muscle. *J Lipid Res*. 2001;42:1041–8.
25. **Howald H, Boesch C, Kreis R, et al.** Content of intramyocellular lipids derived by electron microscopy, biochemical assays, and (1)H-MR spectroscopy. *J Appl Physiol*. 2002;92:2264–72.

26. **Thornell LE, Carlsson E, Kugelberg E, Grove BK.** Myofibrillar M-band structure and composition of physiologically defined rat motor units. *Am J Physiol.* 1987;253:C456–68.
27. **Bayliss-High O.** *Theory and Practice of Histological Techniques.* Edinburgh, UK: Churchill Livingstone; 1977, pp. 168–85.
28. **Goodpaster BH, Theriault R, Watkins SC, Kelley DE.** Intramuscular lipid content is increased in obesity and decreased by weight loss. *Metabolism.* 2000;49:467–72.
29. **Koopman R, Schaart G, Hesselink MK.** Optimisation of oil red O staining permits combination with immunofluorescence and automated quantification of lipids. *Histochem Cell Biol.* 2001;116:63–8.
30. **Schick F, Eismann B, Jung WI, Bongers H, Bunse M, Lutz O.** Comparison of localized proton NMR signals of skeletal muscle and fat tissue in vivo: two lipid compartments in muscle tissue. *Magn Reson Med.* 1993;29:158–67.
31. **Boesch C, Slotboom J, Hoppeler H, Kreis R.** In vivo determination of intra-myocellular lipids in human muscle by means of localized 1H-MR-spectroscopy. *Magn Reson Med.* 1997;37:484–93.
32. **Szczepaniak LS, Dobbins RL, Stein DT, McGarry JD.** Bulk magnetic susceptibility effects on the assessment of intra- and extramyocellular lipids in vivo. *Magn Reson Med.* 2002;47:607–10.
33. **Schrauwen-Hinderling VB, Schrauwen P, Hesselink MK, et al.** The increase in intramyocellular lipid content is a very early response to training. *J Clin Endocrinol Metab.* 2003;88:1610–6.
34. **Rico-Sanz J, Hajnal JV, Thomas EL, Mierisova S, Ala-Korpela M, Bell JD.** Intracellular and extracellular skeletal muscle triglyceride metabolism during alternating intensity exercise in humans. *J Physiol (Lond).* 1998;510:615–22.
35. **Szczepaniak LS, Babcock EE, Schick F, et al.** Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. *Am J Physiol.* 1999;276:E977–89.
36. **Brechtel K, Machann J, Jacob S, et al.** In-vivo 1H-MR spectroscopy: the determination of the intra- and extramyocellular lipid content depending on the insulin effect in the direct offspring of type-2 diabetics. *Rofo.* 1999;171:113–20.
37. **Arrowsmith FE, Ward J, Rooney K, Kriketos AD, Baur LA, Thompson CH.** Body fatness, insulin sensitivity and muscle oxygen supply in adolescents. *Clin Sci (Lond).* 2002;103:391–6.
38. **Vermathen P, Kreis R, Boesch C.** Distribution of intramyocellular lipids in human calf muscles as determined by MR spectroscopic imaging. *Magn Reson Med.* 2004;51:253–62.
39. **Goodpaster BH, Stenger VA, Boada F, et al.** Skeletal muscle lipid concentration quantified by magnetic resonance imaging. *Am J Clin Nutr.* 2004;79:748–54.
40. **Schick F, Machann J, Brechtel K, et al.** MRI of muscular fat. *Magn Reson Med.* 2002;47:720–7.
41. **Goodpaster BH, Kelley DE, Thaete FL, He J, Ross R.** Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content. *J Appl Physiol.* 2000;89:104–10.
42. **van Loon LJ, Schrauwen-Hinderling VB, Koopman R, et al.** Influence of prolonged endurance cycling and recovery diet on intramuscular triglyceride content in trained males. *Am J Physiol Endocrinol Metab.* 2003;285:E804–11.
43. **Carlson LA, Ekelund LG, Froberg SO.** Concentration of triglycerides, phospholipids and glycogen in skeletal muscle and of free fatty acids and beta-hydroxybutyric acid in blood in man in response to exercise. *Eur J Clin Invest.* 1971;1:248–54.
44. **Bergstrom J, Hultman E, Saltin B.** Muscle glycogen consumption during cross-country skiing (the Vasa ski race). *Int Z Angew Physiol.* 1973;31:71–5.
45. **Cleroux J, Van Nguyen P, Taylor AW, Leenen FH.** Effects of beta 1- vs. beta 1 + beta 2-blockade on exercise endurance and muscle metabolism in humans. *J Appl Physiol.* 1989;66:548–54.
46. **Costill DL, Gollnick PD, Jansson ED, Saltin B, Stein EM.** Glycogen depletion pattern in human muscle fibres during distance running. *Acta Physiol Scand.* 1973;89:374–83.
47. **Essen B, Jansson E, Henriksson J, Taylor AW, Saltin B.** Metabolic characteristics of fibre types in human skeletal muscle. *Acta Physiol Scand.* 1975;95:153–65.
48. **Froberg SO, Mossfeldt F.** Effect of prolonged strenuous exercise on the concentration of triglycerides, phospholipids and glycogen in muscle of man. *Acta Physiol Scand.* 1971;82:167–71.
49. **Watt MJ, Heigenhauser GJ, Dyck DJ, Spriet LL.** Intramuscular triacylglycerol, glycogen and acetyl group metabolism during 4 h of moderate exercise in man. *J Physiol.* 2002;541:969–78.
50. **Essen-Gustavsson B, Tesch PA.** Glycogen and triglyceride utilization in relation to muscle metabolic characteristics in men performing heavy-resistance exercise. *Eur J Appl Physiol Occup Physiol.* 1990;61:5–10.
51. **Hurley BF, Nemeth PM, Martin WH 3rd, Hagberg JM, Dalsky GP, Holloszy JO.** Muscle triglyceride utilization during exercise: effect of training. *J Appl Physiol.* 1986;60:562–7.
52. **Kiens B, Richter EA.** Utilization of skeletal muscle triacylglycerol during postexercise recovery in humans. *Am J Physiol.* 1998;275:E332–7.
53. **Roepstorff C, Steffensen CH, Madsen M, et al.** Gender differences in substrate utilization during submaximal exercise in endurance-trained subjects. *Am J Physiol Endocrinol Metab.* 2002;282:E435–47.
54. **Starling RD, Trappe TA, Parcell AC, Kerr CG, Fink WJ, Costill DL.** Effects of diet on muscle triglyceride and endurance performance. *J Appl Physiol.* 1997;82:1185–9.
55. **Staron RS, Hikida RS, Murray TF, Hagerman FC, Hagerman MT.** Lipid depletion and repletion in skeletal muscle following a marathon. *J Neurol Sci.* 1989;94:29–40.
56. **Kayar SR, Hoppeler H, Howald H, Claassen H, Oberholzer F.** Acute effects of endurance exercise on mitochondrial distribution and skeletal muscle morphology. *Eur J Appl Physiol Occup Physiol.* 1986;54:578–84.
57. **Boesch C, Decombaz J, Slotboom J, Kreis R.** Observation of intramyocellular lipids by means of 1H magnetic resonance spectroscopy. *Proc Nutr Soc.* 1999;58:841–50.
58. **Krssak M, Petersen KF, Bergeron R, et al.** Intramuscular glycogen and intramyocellular lipid utilization during pro-

- longed exercise and recovery in man: a ^{13}C and ^1H nuclear magnetic resonance spectroscopy study. *J Clin Endocrinol Metab.* 2000;85:748–54.
59. **Rico-Sanz J, Moosavi M, Thomas EL, et al.** In vivo evaluation of the effects of continuous exercise on skeletal muscle triglycerides in trained humans. *Lipids.* 2000;35:1313–8.
 60. **Brechtel K, Niess AM, Machann J, et al.** Utilisation of intramyocellular lipids (IMCLs) during exercise as assessed by proton magnetic resonance spectroscopy (^1H -MRS). *Horm Metab Res.* 2001;33:63–6.
 61. **Decombaz J, Schmitt B, Ith M, et al.** Postexercise fat intake repletes intramyocellular lipids but no faster in trained than in sedentary subjects. *Am J Physiol Regul Integr Comp Physiol.* 2001;281:R760–9.
 62. **Larson-Meyer DE, Newcomer BR, Hunter GR.** Influence of endurance running and recovery diet on intramyocellular lipid content in women: a ^1H NMR study. *Am J Physiol Endocrinol Metab.* 2002;282:E95–E106.
 63. **Schrauwen-Hinderling VB, van Loon LJ, Koopman R, Nicolay K, Saris WH, Kooi ME.** Intramyocellular lipid content is increased after exercise in nonexercising human skeletal muscle. *J Appl Physiol.* 2003;95:2328–32.
 64. **White LJ, Robergs RA, Sibbitt WL Jr, Ferguson MA, McCoy S, Brooks WM.** Effects of intermittent cycle exercise on intramyocellular lipid use and recovery. *Lipids.* 2003;38:9–13.
 65. **Hwang JH, Pan JW, Heydari S, Hetherington HP, Stein DT.** Regional differences in intramyocellular lipids in humans observed by in vivo ^1H -MR spectroscopic imaging. *J Appl Physiol.* 2001;90:1267–74.
 66. **Johnson MA, Polgar J, Weightman D, Appleton D.** Data on the distribution of fibre types in thirty-six human muscles. An autopsy study. *J Neurol Sci.* 1973;18:111–29.
 67. **Howald H, Hoppeler H, Claassen H, Mathieu O, Straub R.** Influences of endurance training on the ultrastructural composition of the different muscle fiber types in humans. *Pflugers Arch.* 1985;403:369–76.
 68. **van Loon LJ, Koopman R, Manders R, van der Weegen W, van Kranenburg GP, Keizer HA.** Intramyocellular lipid content in type 2 diabetes patients compared with overweight sedentary men and highly trained endurance athletes. *Am J Physiol Endocrinol Metab.* 2004;287:E558–65.
 69. **Decombaz J, Fleith M, Hoppeler H, Kreis R, Boesch C.** Effect of diet on the replenishment of intramyocellular lipids after exercise. *Eur J Nutr.* 2000;39:244–7.
 70. **Lambert EV, Speechly DP, Dennis SC, Noakes TD.** Enhanced endurance in trained cyclists during moderate intensity exercise following 2 weeks adaptation to a high fat diet. *Eur J Appl Physiol Occup Physiol.* 1994;69:287–93.
 71. **O'Keefe KA, Keith RE, Wilson GD, Blessing DL.** Dietary carbohydrate intake and endurance exercise performance of trained female cyclists. *Nutr Res.* 1989;9:819–30.
 72. **Phinney SD, Bistrian BR, Evans WJ, Gervino E, Blackburn GL.** The human metabolic response to chronic ketosis without caloric restriction: preservation of submaximal exercise capability with reduced carbohydrate oxidation. *Metabolism.* 1983;32:769–76.
 73. **Goedecke JH, Christie C, Wilson G, et al.** Metabolic adaptations to a high-fat diet in endurance cyclists. *Metabolism.* 1999;48:1509–17.
 74. **Rowlands DS, Hopkins WG.** Effects of high-fat and high-carbohydrate diets on metabolism and performance in cycling. *Metabolism.* 2002;51:678–90.
 75. **Burke LM, Kiens B, Ivy JL.** Carbohydrates and fat for training and recovery. *J Sports Sci.* 2004;22:15–30.
 76. **Phillips SM, Green HJ, Tarnopolsky MA, Heigenhauser GJ, Grant SM.** Progressive effect of endurance training on metabolic adaptations in working skeletal muscle. *Am J Physiol.* 1996;270:E265–72.
 77. **Bergman BC, Butterfield GE, Wolfel EE, Casazza GA, Lopaschuk GD, Brooks GA.** Evaluation of exercise and training on muscle lipid metabolism. *Am J Physiol.* 1999;276:E106–17.
 78. **Trendafilov B, Tanushev M.** Morphometrische Untersuchungen an Skelettmuskeln von Wettkämpfern im Rudern. *Med Sport.* 1981;21:264–8.
 79. **Kiessling KH, Pilstrom L, Bylund AC, Saltin B, Piehl K.** Enzyme activities and morphometry in skeletal muscle of middle-aged men after training. *Scand J Clin Lab Invest.* 1974;33:63–9.
 80. **Hoppeler H, Howald H, Conley K, et al.** Endurance training in humans: aerobic capacity and structure of skeletal muscle. *J Appl Physiol.* 1985;59:320–7.
 81. **Orlander J, Aniansson A.** Effect of physical training on skeletal muscle metabolism and ultrastructure in 70- to 75-year-old men. *Acta Physiol Scand.* 1980;109:149–54.
 82. **Rosler K, Hoppeler H, Conley KE, Claassen H, Gehr P, Howald H.** Transfer effects in endurance exercise: adaptations in trained and untrained muscles. *Eur J Appl Physiol Occup Physiol.* 1985;54:355–62.
 83. **Alway SE, MacDougall JD, Sale DG, Sutton JR, McComas AJ.** Functional and structural adaptations in skeletal muscle of trained athletes. *J Appl Physiol.* 1988;64:1114–20.
 84. **Prince FP, Hikida RS, Hagerman FC, Staron RS, Allen WH.** A morphometric analysis of human muscle fibers with relation to fiber types and adaptations to exercise. *J Neurol Sci.* 1981;49:165–79.
 85. **Staron RS, Hikida RS, Hagerman FC, Dudley GA, Murray TF.** Human skeletal muscle fiber type adaptability to various workloads. *J Histochem Cytochem.* 1984;32:146–52.
 86. **Friden J, Sjöström M, Ekblom B.** Muscle fibre type characteristics in endurance trained and untrained individuals. *Eur J Appl Physiol Occup Physiol.* 1984;52:266–71.
 87. **Pruchnic R, Katsiaras A, He J, Winters C, Kelley DE, Goodpaster BH.** Exercise training increases intramyocellular lipid and oxidative capacity in older adults. *Am J Physiol Endocrinol Metab.* 2004;287:E857–62.
 88. **Thamer C, Machann J, Bachmann O, et al.** Intramyocellular lipids: anthropometric determinants and relationships with maximal aerobic capacity and insulin sensitivity. *J Clin Endocrinol Metab.* 2003;88:1785–91.
 89. **Helge JW, Wulff B, Kiens B.** Impact of a fat-rich diet on endurance in man: role of the dietary period. *Med Sci Sports Exerc.* 1998;30:456–61.
 90. **Helge JW, Watt PW, Richter EA, Rennie MJ, Kiens B.** Fat utilization during exercise: adaptation to a fat-rich diet

- increases utilization of plasma fatty acids and very low density lipoprotein-triacylglycerol in humans. *J Physiol*. 2001;537:1009–20.
91. **Zderic TW, Davidson CJ, Schenk S, Byerley LO, Coyle EF.** High-fat diet elevates resting intramuscular triglyceride concentration and whole-body lipolysis during exercise. *Am J Physiol Endocrinol Metab*. 2003;286:E217–25.
 92. **Kiens B, Essen-Gustavsson B, Gad P, Lithell H.** Lipoprotein lipase activity and intramuscular triglyceride stores after long-term high-fat and high-carbohydrate diets in physically trained men. *Clin Physiol*. 1987;7:1–9.
 93. **Jansson E, Kaijser L.** Effect of diet on muscle glycogen and blood glucose utilization during a short-term exercise in man. *Acta Physiol Scand*. 1982;115:341–7.
 94. **Vogt M, Puntchart A, Howald H, et al.** Effects of dietary fat on muscle substrates, metabolism, and performance in athletes. *Med Sci Sports Exerc*. 2003;35:952–60.
 95. **Bachmann OP, Dahl DB, Brechtel K, et al.** Effects of intravenous and dietary lipid challenge on intramyocellular lipid content and the relation with insulin sensitivity in humans. *Diabetes*. 2001;50:2579–84.
 96. **Johnson NA, Stannard SR, Mehalski K, et al.** Intramyocellular triacylglycerol in prolonged cycling with high- and low-carbohydrate availability. *J Appl Physiol*. 2003;94:1365–72.
 97. **Schrauwen-Hinderling VB, Kooi ME, Hesselink MKC, et al.** Intramyocellular lipid content and molecular adaptations in response to a 1-week high-fat diet. *Obes Res*. 2005;13:2088–94.
 98. **Schrauwen P, Wagenmakers AJ, van Marken Lichtenbelt WD, Saris WH, Westerterp KR.** Increase in fat oxidation on a high-fat diet is accompanied by an increase in triglyceride-derived fatty acid oxidation. *Diabetes*. 2000;49:640–6.
 99. **Perseghin G, Scifo P, Danna M, et al.** Normal insulin sensitivity and IMCL content in overweight humans are associated with higher fasting lipid oxidation. *Am J Physiol Endocrinol Metab*. 2002;283:E556–64.
 100. **Boden G, Lebed B, Schatz M, Homko C, Lemieux S.** Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. *Diabetes*. 2001;50:1612–7.
 101. **Stannard SR, Thompson MW, Fairbairn K, Huard B, Sachinwalla T, Thompson CH.** Fasting for 72 h increases intramyocellular lipid content in nondiabetic, physically fit men. *Am J Physiol Endocrinol Metab*. 2002;283:E1185–91.
 102. **Phillips DI, Caddy S, Ilic V, et al.** Intramuscular triglyceride and muscle insulin sensitivity: evidence for a relationship in nondiabetic subjects. *Metabolism*. 1996;45:947–50.
 103. **Perseghin G, Scifo P, De Cobelli F, et al.** Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a ^1H – ^{13}C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. *Diabetes*. 1999;48:1600–6.
 104. **Jacob S, Machann J, Rett K, et al.** Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects. *Diabetes*. 1999;48:1113–9.
 105. **Falholt K, Jensen I, Lindkaer Jensen S, et al.** Carbohydrate and lipid metabolism of skeletal muscle in type 2 diabetic patients. *Diabet Med*. 1988;5:27–31.
 106. **Gray RE, Tanner CJ, Pories WJ, MacDonald KG, Houmard JA.** Effect of weight loss on muscle lipid content in morbidly obese subjects. *Am J Physiol Endocrinol Metab*. 2003;284:E726–32.
 107. **Greco AV, Mingrone G, Giancaterini A, et al.** Insulin resistance in morbid obesity: reversal with intramyocellular fat depletion. *Diabetes*. 2002;51:144–51.
 108. **Tunstall RJ, Mehan KA, Wadley GD, et al.** Exercise training increases lipid metabolism gene expression in human skeletal muscle. *Am J Physiol Endocrinol Metab*. 2002;283:E66–72.
 109. **Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI.** Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. *N Engl J Med*. 2004;350:664–71.
 110. **Shulman GI.** Cellular mechanisms of insulin resistance. *J Clin Invest*. 2000;106:171–6.
 111. **Bramble DM, Lieberman DE.** Endurance running and the evolution of Homo. *Nature*. 2004;432:345–52.